成纤维细胞激活蛋白α靶向成像与治疗孤立性纤维性肿瘤
该研究分析孤立性纤维性肿瘤中FAPα的表达,并在患者中评估68Ga-FAPI-46 PET成像和90Y-FAPI-46放射配体治疗的潜力。SFT具有最高的FAPα mRNA中位表达,68Ga-FAPI-46 PET肿瘤摄取和检测效能优于18F-FDG PET,90Y-FAPI-46治疗使9例(82%)患者疾病控制。
要点
- SFT在813例患者126种肿瘤实体中具有最高的FAPα mRNA中位表达。
- 68Ga-FAPI-46 PET的SUVmax为13.2,检测效能94.5%,优于18F-FDG PET。
- 90Y-FAPI-46治疗34周期后9例(82%)疾病控制,中位无进展生存227天。
核心结论
- FAPα在SFT中高表达,可能作为成像和治疗的靶点。
- 需要进一步研究来确定FAPα靶向诊疗在SFT患者管理中的作用。
研究设计与样本
- 分析来自德国癌症联盟前瞻性观察性MASTER计划的813例患者和126种肿瘤实体的FAPα mRNA和蛋白表达。
- 在独立队列38例SFT患者活检样本中验证蛋白表达。
- 19例患者接受临床68Ga-FAPI-46 PET、18F-FDG PET和增强CT评估。
- 11例进展性SFT患者接受90Y-FAPI-46放射配体治疗。
主要发现
- SFT(n=34)在813例患者和126种肿瘤实体中具有最高的FAPα mRNA中位表达。
- 独立队列38例SFT患者中29例(76%)活检样本确认蛋白表达,24/38例(63%)免疫组化显示中至高表达,主要位于肿瘤细胞表面。
- 19例患者68Ga-FAPI-46 PET的SUVmax为13.2(IQR 10.2),检测效能94.5%(SEM 4.2%);18F-FDG PET的SUVmax为3.2(IQR 3.1),检测效能77.3%(SEM 5.5%)。
- 11例患者接受34周期(中位3周期,IQR 2周期)90Y-FAPI-46治疗,9例(82%)疾病控制,中位无进展生存227天(IQR 220天)。
局限性
- 需要进一步研究来确定FAPα靶向诊疗在SFT患者管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its potential use as a radiotheranostic target. Methods: We analyzed FAPα messenger RNA and protein expression in biopsy samples from SFT patients using immunohistochemistry and multiplexed immunofluorescence. Tracer uptake and detection efficacy were assessed in patients undergoing clinical 68Ga-FAPα inhibitor (FAPI)-46 PET,18F-FDG PET, and contrast-enhanced CT. 90Y-FAPI-46 radioligand therapy was offered to eligible patients with progressive SFT. Results: Among 813 patients and 126 tumor entities analyzed from the prospective observational MASTER program of the German Cancer Consortium, SFT (n = 34) had the highest median FAPα messenger RNA expression. Protein expression was confirmed in tumor biopsies from 29 of 38 SFT patients (76%) in an independent cohort. Most cases showed intermediate to high FAPα expression by immunohistochemistry (24/38 samples, 63%), which was located primarily on the tumor cell surface. Nineteen patients who underwent 68Ga-FAPI-46 PET imaging demonstrated significantly increased tumor uptake, with an SUVmax of 13.2 (interquartile range [IQR], 10.2), and an improved mean detection efficacy of 94.5% (SEM, 4.2%), as compared with 18F-FDG PET (SUVmax, 3.2 [IQR, 3.1]; detection efficacy, 77.3% [SEM, 5.5%]). Eleven patients received a total of 34 cycles (median, 3 cycles [IQR, 2 cycles]) of 90Y-FAPI-46 radioligand therapy, which resulted in disease control in 9 patients (82%). Median progression-free survival was 227 d (IQR, 220 d). Conclusion: FAPα is highly expressed by SFT and may serve as a target for imaging and therapy. Further studies are warranted to define the role of FAPα-directed theranostics in the care of SFT patients.
引用
- Hamacher R, Pabst KM, Cheung PF, et al. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024. PMID: 38176718. doi:10.2967/jnumed.123.266411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。